Pancreatic Carcinoma with Prominent Mucin Production: A Clinicopathologic and Immunohistochemical Study of 9 Cases

Makoto Saito, Hiroshi Nishihara, Mishie Tanino, Taichi Kimura, Yoshihiro Matsuno, Kazuo Nagashima, Michio Shimizu, Shinya Tanaka

Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;.
Department of Pathology, Saitama Medical University, Saitama, Japan..
Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

DOI: 10.4236/ojpathology.2012.22003                

Abstract

Pancreatic carcinoma occasionally associated with prominent mucin production and this type of tumor designated as PCM (pancreatic carcinoma with prominent mucin production) was diagnosed depends on subjective estimation of the amount of mucous area, and there has been no report on a quantitative evaluation of the amount of mucinous area in the tumor. To examine the feature of PCM, we analyzed 9 cases of PCM among 243 cases of pancreas carcinoma and evaluated the amount of mucin by imaging analysis. Morphologically, 5 cases were classified as intradactal papillary mucinous neoplasms (IPMN)-derived PCM and 4 cases were as ductal adenocarcinoma (DA)-derived PCM. Mucous composition was found to be more than 50% in all IPMN-derived PCM cases, and that was 40% - 50% in DA-derived PCM cases with one exception. IPMN-derived PCM cases showed expansive growth with pancreatic duct dilatation filled with mucin, while DA-derived PCM cases possessed mucin infiltration into interstitial tissue. Immunohisto-chemically, three of 4 DA-derived PCM cases were MUC1(–)/MUC2(+), and the results of expressions for p16 and Dpc4 suggesting that DA-derived PCM was similar to IPMN-derived PCM rather than ordinary DA. Survival rate of DA-derived PCM cases was lower than that of IPMN-derived PCM cases. We advocate that DA-derived PCM may constitute a borderline group between IPMN and ordinary DA.

Keywords

Pancreatic Carcinoma with Prominent Mucin Production (PCM); Mucinous Non-Cystic Carcinoma (MNCC); Intraductal Papillary Mucinous Neoplasm (IPMN); Ductal Adenocarcinoma (DA); Immunohistochemistry

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	K. Suda, B. Nobukawa, S. Yamasaki, F. Suzuki, H. Shimizu and M. Takase, “Pre-Existing Histological Type and Developmental Mechanism of Mucinous Noncystic Carcinoma of Pancreas,” Pathology & Oncology Research, Vol. 6, No. 2, 2000, pp. 125-129. doi:10.1007/BF03032362
[2]	N. V. Adsay, C. Pierson, F. Sarkar, J. Abrams, D. Weaver, K. C. Conlon, M. F. Brennan and D. S. Klimstra, “Colloid (Mucinous Noncystic) Carcinoma of the Pancreas,” American Journal of Surgical Pathology, Vol. 25, No. 1, 2001, pp. 26-42. doi:10.1097/00000478-200101000-00003
[3]	G. Seidel, M. Zahurak, C. Iacobuzio-Donahue, T. A. Sohn, N. V. Adsay, C. J. Yeo, K. D. Lillemoe, J. L. Caeron, R. H. Hruban and R. E. Wilentz, “Almost All Infiltrating Colloid Carcinomas of the Pancreas and Periampullary Region Arise from in Situ Papillary Neoplasms: A Study of 39 Cases,” American Journal of Surgical Pathology, Vol. 26, No. 1, 2002, pp. 56-63. doi:10.1097/00000478-200201000-00006
[4]	R. H. Hruban, M. B. Pitman and D. S. Klimstra, “Tumors of the Pancreas, Afip Atlas of Tumor Pathology, 4th Series Fascicle 6,” 6th Edition, American Registry of Pathology, Washington DC, 2007.
[5]	J. Lüttges, G. Zamboni, D. Longnecker and G. Kloppel, “The Immunohistochemical Mucin Expression Pattern Distinguishes Different Types of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Determines Their Relationship to Mucinous Noncystic Carcinoma and Ductal Adenocarcinoma,” American Journal of Surgical Pathology, Vol. 25, No. 7, 2001, pp. 942-948. doi:10.1097/00000478-200107000-00014
[6]	N. V. Adsay, K. Merati, A. Andea, F. Sarkar, R. H. Hruban, R. E. Wilentz, M. Goggins, C. IocobuzioDonahue, D. S. Longnecker and D. S. Klimstra, “The Dichotomy in the Preinvasive Neoplasia to Invasive Carcinoma Sequence in the Pancreas: Differential Expression of MUC1 and MUC2 Supports the Existence of Two Separate Pathways of Carcinogenesis,” Modern Pathology, vol. 15, No. 10, 2002, pp. 1087-1095. doi:10.1097/01.MP.0000028647.98725.8B
[7]	S. R.Hamilton and L. A. Aaltonen, “World Health Organization Classification of Tumours; Pathology & Genetics, Tumours of the Digestive System,” IARC Press, Lyon, 2000.
[8]	Y. Kawarada, “Classification of Pancreatic Carcinoma,” 2nd English Edition, Japan Pancreas Society, Tokyo, 2003.
[9]	J. Lüttges, K. Beyser, S. Pust, A. Paulus, J. Ruschoff and G. Kloppel, “Pancreatic Mucinous Noncystic (Colloid) Carcinomas and Intraductal Papillary Mucinous Carcinomas Are Usually Microsatellite Stable,” Modern Pathology, Vol. 16, No. 6, 2003, pp. 537-342. doi:10.1097/01.MP.0000072748.65178.2F
[10]	R. H. Hruban, N. V. Adsay, J. Albores-Saavedra, C. Compton, E. S. Garrett, S. N. Goodman, S. E. Kern, D. S. Klimstra, G. Kloppel, D. S. Longnecker, J. Lüttges and G. J. Offerhaus, “Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions,” American Journal of Surgical Pathology, Vol. 25, No. 5, 2001, pp. 579-586. doi:10.1097/00000478-200105000-00003
[11]	A. Maitra, N. V. Adsay, P. Argani, C. Iacobuzio-Donahue, A. De Marzo, J. L. Cameron, C. J. Yeo and R. H. Hruban, “Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray,” Modern Pathology, Vol. 16, No. 9, 2003, pp. 902-912. doi:10.1097/01.MP.0000086072.56290.FB
[12]	A. V. Biankin, J. G. Kench, A. L. Morey, C. S. Lee, S. A. Biankin, D. R. Head, T. B. Hugh, S. M. Henshall and R. L. Sutherland, “Overexpression of p21(WAF1/CIP1) Is an Early Event in the Development of Pancreatic Intraepithelial Neoplasia,” Cancer Research, Vol. 61, No. 24, 2001, pp. 8830-8837.
[13]	A. V. Biankin, S. A. Biankin, J. G. Kench, A. L. Morey, C. S. Lee, D. R. Head, R. P. Eckstein, T. B. Hugh, S. M. Henshall and R. L. Sutherland, “Aberrant p16 (Ink4a) and Dpc4/Smad4 Expression in Intraductal Papillary Mucinous Tumours of the Pancreas Is Associated with Invasive Ductal Adenocarcinoma,” Gut, Vol. 50, No. 6, 2002, pp. 861-868.
[14]	R. H. Hruban, K. Takaori, D. S. Klimstra, N. V. Adsay, J. Albores-Saavedra, A. V. Biankin, S. A. Biankin, C. Compton, N. Fukushima, T. Furukawa, M. Goggins, Y. Kato, G. Kloppel, D. S. Longnecker, J. Lüttges, A. Maitra, G. J. Offerhaus, M. Shimizu and S. Yonezawa, “An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms,” American Journal of Surgical Pathology, Vol. 28, No. 8, 2004, pp. 977-987. doi:10.1097/01.pas.0000126675.59108.8
[15]	A. V. Biankin, J. G. Kench, S. A. Biankin, C. S. Lee, A. L. Morey, F. P. Dijkman, M. J. Coleman, R. L. Sutherland and S. M. Henshall, “Pancreatic Intraepithelial Neoplasia in Association with Intraductal Papillary Mucinous Neoplasms of the Pancreas: Implications for Disease Progression and Recurrence,” American Journal of Surgical Pathology, Vol. 28, No. 9, 2004, pp. 1184-1192. doi:10.1097/01.pas.0000131556.22382.3c
[16]	A. Nakamura, M. Horinouchi, M. Goto, K. Nagata, K. Sakoda, S. Takao, K. Imai, Y. S. Kim, E. Sato and S. Yonezawa, “New Classification of Pancreatic Intraductal Papillary-Mucinous Tumour by Mucin Expression: Its Relationship with Potential for Malignancy,” Journal of Pathology, Vol. 197, No. 2, 2002, pp. 201-210. doi:10.1002/path.1109
[17]	N. V. Adsay, K. Merati, O. Basturk, C. IacobuzioDonahue, E. Levi, J. D. Cheng, F. H. Sarkar, R. H. Hruban and D. S. Klimstra, “Pathologically and Biologically Distinct Types of Epithelium in Intraductal Papillary Mucinous Neoplasms: Delineation of an ‘Intestinal’ Pathway of Carcinogenesis in the Pancreas,” American Journal of Surgical Pathology, Vol. 28, No. 7, 2004, pp. 839-848. doi:10.1097/00000478-200407000-00001
[18]	T. Furukawa, G. Kl?ppel, N. Volkan Adsay, J. AlboresSaavedra, N. Fukushima, A. Horii, R. H. Hruban, Y. Kato, D. S. Klimstra, D. S. Longnecker, J. Lüttges, G. J. Offerhaus, M. Shimizu, M. Sunamura, A. Suriawinata, K. Takaori and S. Yonezawa, “Classification of Types of Intraductal Papillary-Mucinous Neoplasm of the Pancreas: A Consensus Study,” Virchows Archiv, Vol. 447, No. 5, 2005, pp. 794-799. doi:10.1007/s00428-005-0039-7
[19]	K. M. Alle, S. M. Henshall, A. S. Field and R. L. Sutherland, “Cyclin D1 Protein Is Overexpressed in Hyperplasia and Intraductal Carcinoma of the Breast,” Clinical Cancer Research, Vol. 4, No. 4, 1998, pp. 847-854.
[20]	R. J. Bova, D. I. Quinn, J. S. Nankervis, I. E. Cole, B. F. Sheridan, M. J. Jensen, G. J. Morgan, C. J. Hughes and R. L. Sutherland, “Cyclin D1 and p16INK4A Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue,” Clinical Cancer Research, Vol. 5, No. 10, 1999, pp. 2810-2819.
[21]	R. E. Wilentz, J. Geradts, R. Maynard, G. J. Offerhaus, M. Kang, M. Goggins, C. J. Yeo, S. E. Kern and R. H. Hruban, “Inactivation of the p16 (Ink4a) Tumor-Suppressor Gene in Pancreatic Duct Lesions: Loss of Intranuclear Expression,” Cancer Research, Vol. 58, No. 20, 1998, pp. 4740-4744.
[22]	K. M. Alle, S. M. Henshall, A. S. Field and R. L. Sutherland, “Cyclin D1 Protein Is Overexpressed in Hyperplasia and Intraductal Carcinoma of the Breast,” Clinical Cancer Research, Vol. 4, No. 4, 1998, pp. 847-854.